Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News

Novo Nordisk Stock Dips as Eli Lilly’s Mounjaro Outshines Wegovy in Weight Loss

by Team Lumida
July 9, 2024
in News
Reading Time: 3 mins read
A A
0
Novo Nordisk Stock Dips as Eli Lilly’s Mounjaro Outshines Wegovy in Weight Loss

"Two Boxes of Ozempic (Semagalutide) / Wegovy Pens - 0.25mg and 0.5mg" by chemist4u is licensed under CC BY 2.0

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

  1. Novo Nordisk shares drop 1.1% after study favors Eli Lilly’s Mounjaro.
  2. Mounjaro users 76% more likely to lose 5% body weight than Ozempic users.
  3. Weight-loss drug market could hit $150 billion annually by early 2030s.

What Happened?

Novo Nordisk shares fell 1.1% on Tuesday following a JAMA Internal Medicine analysis showing Eli Lilly’s Mounjaro leads to faster and more significant weight loss compared to Novo’s Ozempic. The study examined health records and pharmacy data for 9,193 patients on Mounjaro and a similar number on Ozempic.

Results indicated Mounjaro users were 76% more likely to lose at least 5% of their body weight, twice as likely to lose 10%, and three times as likely to lose 15%. The average participant weighed 242 pounds, and about half had type 2 diabetes.

Why It Matters?

For investors, this data is crucial. The weight-loss drug market is booming and could be worth $150 billion annually by the early 2030s. Novo Nordisk and Eli Lilly are key players, historically dominating the insulin market. However, this study shifts the competitive landscape.

Novo Nordisk noted that the analysis did not include its Wegovy drug, emphasizing the need for head-to-head clinical trials for an accurate comparison. Eli Lilly’s Mounjaro showing better results could influence market share and profitability.

What’s Next?

Investors should monitor upcoming clinical trials comparing these weight-loss drugs directly. Novo Nordisk aims to bolster its market position by emphasizing Wegovy’s effectiveness. Meanwhile, Eli Lilly will likely continue capitalizing on Mounjaro’s superior results.

The competition will likely intensify as both companies race to scale up production to meet the soaring demand. Keep an eye on future regulatory approvals, market expansions, and any new data that could sway market dynamics further.

Source: Investing.com
Tags: Eli LillyMounjaroNovo NordiskOzempicweight-loss drugs
Previous Post

Taiwan Exports Surge 23.5% in June: AI Demand Fuels Massive Growth

Next Post

Fed’s Rule Tweak Could Save Big Banks Billions – What You Need to Know

Recommended For You

Corporate Pension Funds Shift Strategies Amid Full Funding, Impacting Bonds and Private Equity

by Team Lumida
2 hours ago
a computer screen with a bunch of data on it

Key Takeaways: Powered by lumidawealth.com Corporate pension funds, with over $3 trillion in assets, have reached a healthier financial state, with the largest 100 U.S. corporate pensions achieving a...

Read more

Trump Administration Expands Federal Contract Review to Target Tech Firms

by Team Lumida
3 hours ago
Trump Administration Expands Federal Contract Review to Target Tech Firms

Key Takeaways: Powered by lumidawealth.com The Trump administration is broadening its cost-cutting review of federal contracts to include technology providers, following earlier scrutiny of consulting firms. The General Services...

Read more

JPMorgan’s Jamie Dimon Warns of Bond Market Crisis Amid U.S. Fiscal Challenges

by Team Lumida
1 day ago
Tax-Loss Harvesting Surge: JPMorgan’s $15 Billion Windfall

Key Takeaways: Powered by lumidawealth.com JPMorgan CEO Jamie Dimon predicts a “crack in the bond market” unless the U.S. addresses its spiraling national debt, which now exceeds $36 trillion....

Read more

Trump to Raise Steel and Aluminum Tariffs to 50% Amid US Steel-Nippon Deal Announcement

by Team Lumida
1 day ago
Trump Announces 25% Tariffs on Mexico and Canada, Targeting Border Security and Trade

Key Takeaways: Powered by lumidawealth.com President Trump announced an increase in steel and aluminum tariffs from 25% to 50%, citing the need to protect American workers and industries. The...

Read more

US-China Trade Talks ‘Stalled,’ Trump-Xi Call May Be Needed, Says Treasury Secretary Bessent

by Team Lumida
2 days ago
US-China Trade Talks ‘Stalled,’ Trump-Xi Call May Be Needed, Says Treasury Secretary Bessent

Key Takeaways: Powered by lumidawealth.com US Treasury Secretary Scott Bessent described US-China trade talks as “a bit stalled” and suggested a call between President Trump and President Xi Jinping...

Read more

Trump’s Team Prepares Alternative Tariff Strategy Amid Legal Challenges

by Team Lumida
2 days ago
Fed Official Warns of Inflation Risks Under Trump Presidency

Key Takeaways: Powered by lumidawealth.com A federal trade court ruled Trump’s use of emergency economic powers to impose sweeping tariffs as illegal, but an appeals court has temporarily allowed...

Read more

BlackRock’s Bitcoin ETF Sees Record $6.35 Billion Inflows Amid May Rally

by Team Lumida
2 days ago
Is BlackRock the New Leader in Alternative Investments?

Key Takeaways: Powered by lumidawealth.com BlackRock’s iShares Bitcoin Trust (IBIT) recorded its largest-ever monthly inflow in May, attracting $6.35 billion and lifting total assets under management to over $71...

Read more

Costco Mitigates Tariff Impact Through Strategic Sourcing and Order Advancements

by Team Lumida
2 days ago
Costco Mitigates Tariff Impact Through Strategic Sourcing and Order Advancements

Key Takeaways: Powered by lumidawealth.com Costco is reducing tariff exposure by pulling orders forward and shifting private-label product sourcing to regions where they are sold, helping to control costs...

Read more

Trump Pressures Fed Chair Powell to Cut Interest Rates, Citing Economic Disadvantage

by Team Lumida
2 days ago
Will September’s Fed Rate Cuts Surprise Investors? Here’s What Deutsche Bank Predicts

Key Takeaways: Powered by lumidawealth.com President Trump met with Federal Reserve Chair Jerome Powell, urging him to lower interest rates, claiming current levels put the U.S. at an economic...

Read more

Chinese Tech Stocks Slide as U.S.-China Trade Talks Stall

by Team Lumida
2 days ago
Chinese Stock Surge: A Hedge Fund Headache?

Key Takeaways: Powered by lumidawealth.com Chinese tech stocks fell sharply, with Alibaba down 4.2%, BYD dropping 3.8%, and Baidu losing 3.9%, as the Hang Seng Tech Index declined 2.7%....

Read more
Next Post
bank, money, finance

Fed’s Rule Tweak Could Save Big Banks Billions – What You Need to Know

red and black metal tower during sunset

The World's Largest Oil Company Believes Petrol Engines Will Outlast Electric Cars

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

turned on flat screen monitor

US Stock Futures Rise as Investors Eye Powell’s Speech: What’s Next?

August 23, 2024
Trump Announces 25% Tariffs on Mexico and Canada, Targeting Border Security and Trade

Trump Acknowledges Economic Turbulence Amid Sweeping Reforms, Declines to Rule Out Recession

March 10, 2025
Tech Titans Pivot: Silicon Valley’s New Alliance in Trump’s Second Term

Trump’s Tariffs Could Make the iPhone a “Bajillion-Dollar” Device

April 6, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018